Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt No Debt
GTXI's Cash to Debt is ranked higher than
96% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: 61.14 vs. GTXI: No Debt )
Ranked among companies with meaningful Cash to Debt only.
GTXI' s Cash to Debt Range Over the Past 10 Years
Min: 2688.67  Med: 10000.00 Max: No Debt
Current: No Debt
Interest Coverage No Debt
GTXI's Interest Coverage is ranked higher than
95% of the 393 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. GTXI: No Debt )
Ranked among companies with meaningful Interest Coverage only.
GTXI' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: 10000.00 Max: 9999.99
Current: No Debt
N/A
9999.99
F-Score: 2
Z-Score: -22.05
M-Score: -6.89
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
ROE (%) -1089.03
GTXI's ROE (%) is ranked lower than
98% of the 859 Companies
in the Global Biotechnology industry.

( Industry Median: -31.46 vs. GTXI: -1089.03 )
Ranked among companies with meaningful ROE (%) only.
GTXI' s ROE (%) Range Over the Past 10 Years
Min: -397.59  Med: -73.61 Max: 71.17
Current: -1089.03
-397.59
71.17
ROA (%) -44.94
GTXI's ROA (%) is ranked lower than
66% of the 939 Companies
in the Global Biotechnology industry.

( Industry Median: -26.29 vs. GTXI: -44.94 )
Ranked among companies with meaningful ROA (%) only.
GTXI' s ROA (%) Range Over the Past 10 Years
Min: -118.97  Med: -42.47 Max: 25.08
Current: -44.94
-118.97
25.08
ROC (Joel Greenblatt) (%) -156007.14
GTXI's ROC (Joel Greenblatt) (%) is ranked lower than
99% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -363.62 vs. GTXI: -156007.14 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
GTXI' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -128476.47  Med: -2350.66 Max: 522.64
Current: -156007.14
-128476.47
522.64
EBITDA Growth (3Y)(%) -42.50
GTXI's EBITDA Growth (3Y)(%) is ranked lower than
90% of the 497 Companies
in the Global Biotechnology industry.

( Industry Median: -0.30 vs. GTXI: -42.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
GTXI' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -15.60 Max: 10.4
Current: -42.5
0
10.4
EPS Growth (3Y)(%) -41.10
GTXI's EPS Growth (3Y)(%) is ranked lower than
86% of the 487 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. GTXI: -41.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
GTXI' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -54.8  Med: -6.00 Max: 194
Current: -41.1
-54.8
194
» GTXI's 10-Y Financials

Financials (Next Earnings Date: 2016-05-10)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

GTXI Guru Trades in Q1 2015

Paul Tudor Jones 34,033 sh (unchged)
» More
Q2 2015

GTXI Guru Trades in Q2 2015

Paul Tudor Jones 34,033 sh (unchged)
» More
Q3 2015

GTXI Guru Trades in Q3 2015

Paul Tudor Jones 34,033 sh (unchged)
» More
Q4 2015

GTXI Guru Trades in Q4 2015

Paul Tudor Jones 34,033 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with GTXI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 53.84
GTXI's P/B is ranked lower than
97% of the 843 Companies
in the Global Biotechnology industry.

( Industry Median: 3.49 vs. GTXI: 53.84 )
Ranked among companies with meaningful P/B only.
GTXI' s P/B Range Over the Past 10 Years
Min: 0.44  Med: 4.53 Max: 12950
Current: 53.84
0.44
12950
Current Ratio 1.06
GTXI's Current Ratio is ranked lower than
89% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.77 vs. GTXI: 1.06 )
Ranked among companies with meaningful Current Ratio only.
GTXI' s Current Ratio Range Over the Past 10 Years
Min: 1.06  Med: 6.76 Max: 13.63
Current: 1.06
1.06
13.63
Quick Ratio 1.06
GTXI's Quick Ratio is ranked lower than
86% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. GTXI: 1.06 )
Ranked among companies with meaningful Quick Ratio only.
GTXI' s Quick Ratio Range Over the Past 10 Years
Min: 1.06  Med: 6.76 Max: 13.54
Current: 1.06
1.06
13.54

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 70.00
GTXI's Price/Net Current Asset Value is ranked lower than
96% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 5.40 vs. GTXI: 70.00 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
GTXI' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.88  Med: 6.08 Max: 70
Current: 70
2.88
70
Price/Tangible Book 70.00
GTXI's Price/Tangible Book is ranked lower than
97% of the 776 Companies
in the Global Biotechnology industry.

( Industry Median: 4.27 vs. GTXI: 70.00 )
Ranked among companies with meaningful Price/Tangible Book only.
GTXI' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.75  Med: 5.89 Max: 58.33
Current: 70
2.75
58.33
Earnings Yield (Greenblatt) (%) -31.26
GTXI's Earnings Yield (Greenblatt) (%) is ranked lower than
77% of the 900 Companies
in the Global Biotechnology industry.

( Industry Median: -7.60 vs. GTXI: -31.26 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
GTXI' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -31.26  Med: 169.05 Max: 3978.9
Current: -31.26
-31.26
3978.9

More Statistics

Revenue(Mil) $14
EPS $ -0.42
Beta2.29
Short Percentage of Float2.80%
52-Week Range $0.29 - 1.59
Shares Outstanding(Mil)141.75

Analyst Estimate

Dec16 Dec17
Revenue(Mil)
EPS($) -0.14 -0.15
EPS without NRI($) -0.14 -0.15

Business Description

Industry: Biotechnology » Biotechnology
Compare:ASX:NEU, OSTO:PROB, AMEX:OCX, NAS:PSTI, LSE:RENE, NAS:CDXS » details
Traded in other countries:GTU.Germany,
GTx Inc is a Delaware corporation incorporated on September 24, 1997. It operates as a biopharmaceutical company dedicated to the discovery, development and commercialization of small molecules that selectively target hormone pathways to treat cancer, osteoporosis and bone loss, muscle loss and other serious medical conditions. The Company develops selective androgen receptor modulators, or SARMs, to prevent and treat muscle wasting in patients with cancer and other musculoskeletal wasting or muscle loss conditions, including chronic sarcopenia (age related muscle loss). They are conducting the POWER 1 and POWER 2 (Prevention and treatment Of muscle Wasting in patients with cancER) pivotal Phase III clinical trials evaluating enobosarm for the prevention and treatment of muscle wasting in patients with advanced non-small cell lung cancer. The Company is developing GTx-758, an oral luteinizing hormone, or LH, inhibitor for the treatment of advanced prostate cancer. In preclinical in vitro and in vivo models, GTx-758 has demonstrated the potential to reduce testosterone to castrate levels without causing certain estrogen deficiency side effects such as bone loss and hot flashes. The Company's most advanced product candidate, toremifene, is being developed for the prevention of bone fractures and treatment of other estrogen deficiency side effects of ADT in men with prostate cancer and for the prevention of prostate cancer in high risk men with high grade PIN. Additionally the company is developing Capesaris (GTx-758), an oral nonsteroidal selective estrogen receptor (ER) alpha agonist, for secondary hormonal therapy in men with metastatic castration resistant prostate cancer, or CRPC, and, potentially, as a primary treatment for advanced prostate cancer used in combination with androgen deprivation therapy, or ADT. It faces competition from many different sources, including commercial pharmaceutical and biotechnology enterprises, academic institutions, government agencies and private and public research institutions.
» More Articles for NAS:GTXI

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: GTx, Inc, VIVUS, Inc, Time Warner Inc. Jul 22 2012 
Weekly CEO Sells Highlight: GTX, Signet Group, Qlik Tech, Voxx Apr 16 2012 
GTx Inc. Reports Operating Results (10-Q) Nov 09 2010 
GTx Inc. Reports Operating Results (10-Q) Aug 09 2010 
GTx Inc. Reports Operating Results (10-Q) May 04 2010 
GTx Inc. Reports Operating Results (10-Q) Nov 09 2009 
GTx Inc. Reports Operating Results (10-Q) Aug 10 2009 
GTx Inc. Reports Operating Results (10-Q) May 11 2009 

More From Other Websites
GTx, Inc. to Report First Quarter 2016 Financial Results on May 10, 2016 Apr 27 2016
GTx, Inc. to Report First Quarter 2016 Financial Results on May 10, 2016 Apr 27 2016
COPsync and GTX Corp Sign Mutual Referral Agreement for Products Targeting Law Enforcement and... Apr 22 2016
Edited Transcript of GTXI earnings conference call or presentation 3-Mar-16 2:00pm GMT Apr 06 2016
GIGABYTE Announces GTX 960 XTREME GAMING Mar 30 2016
GTX INC /DE/ Financials Mar 19 2016
GTX INC /DE/ Files SEC form 10-K, Annual Report Mar 15 2016
GTX Inc Earnings Call scheduled for 9:00 am ET today Mar 03 2016
GTX INC /DE/ Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Mar 03 2016
GTx reports 4Q loss Mar 03 2016
GTx reports 4Q loss Mar 03 2016
Q4 2015 GTX Inc Earnings Release - Before Market Open Mar 03 2016
GTx Provides Corporate Update and Reports Fourth Quarter and Year-End 2015 Financial Results Mar 03 2016
GTx Announces Presentation of Preclinical Data Demonstrating the Effect of GTx SARMs on Pelvic Floor... Feb 24 2016
GTX INC /DE/ Files SEC form 8-K, Change in Directors or Principal Officers Feb 19 2016
GTx, Inc. to Host Fourth Quarter and Full Year 2015 Financial Results Conference Call and Webcast Feb 18 2016
GTX INC /DE/ Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 13 2016
GTx Announces Initiation of Phase 2 Clinical Trial of Enobosarm in Stress Urinary Incontinence Jan 13 2016
GTX INC /DE/ Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule... Dec 23 2015
BIOSTAR GeForce GAMING GTX 750 Ti OC: The Gamer Graphics Card - More performance for the gamer... Dec 18 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK